Educational information, reviewed by Ryan Arvizo, FNP-C. Current as of November 2026.
In 2026, FDA sent warning letters to dozens of telehealth companies, pharmacies and ingredient makers in the compounded-medication space. If you take a compounded medication, you may have seen a headline about a company you recognize. Here is how to read one.
What a warning letter is
When FDA finds significant violations, it notifies the company, “often in the form of a Warning Letter” (FDA, About Warning and Close-Out Letters). The letter lists what FDA found and asks for a response within a set timeframe. The company has “the opportunity to supply FDA with its reasoning and supporting information” if it disagrees. FDA publishes most warning letters on its website, which is why they show up in the news.
Three kinds of letters you will see in this space
1. Marketing claims. In March 2026, FDA announced 30 warning letters to telehealth companies over how they marketed compounded GLP-1 medications. The main problems were “claims implying sameness with FDA-approved products” and branding that implied the telehealth company itself was the compounder (FDA, March 3, 2026). An October 2026 letter to another company cited the phrase “FDA-Approved Compounded Medications” and an “American made” claim (FDA warning letter 737905). These letters are about what a company says, which is still a fair signal about how it operates.
2. Pharmacy practices. Letters to pharmacies and outsourcing facilities usually cite how drugs are made: sterile technique, testing, investigating problems. In 2026, FDA sent letters to a large compounding pharmacy (FDA warning letter 738238) and to a 503B outsourcing facility over sterile-practice failures (FDA warning letter 728537).
3. Ingredient makers. In late 2026, FDA warned overseas makers of ingredients sold for compounding, including for refusing records requests (FDA warning letter 736416). See who actually made the ingredient in your compounded medication.
What happens after a letter
- The company responds. FDA does not publish responses on a fixed schedule, so silence on the page for weeks or months is normal.
- FDA may issue a close-out letter once it has evaluated the company’s corrective actions. FDA says a close-out letter “will not be issued based on representations that some action will or has been taken” (FDA). It is posted on the original letter’s page.
- If problems continue, FDA can take further action, such as import alerts for overseas firms.
What to do if a company you use gets one
- Read the letter itself, not just the headline. Is it about marketing, manufacturing, or a specific product?
- If it is about product quality, check for a related recall (see how to check whether a compounded medication has been recalled).
- Ask your clinic directly whether the company is in its supply chain and what it is doing about it. A good clinic will have an answer.
- Do not stop a prescribed medication on your own without talking to your provider, unless your lot has been recalled.
How BioPeakRx handles it
BioPeakRx runs a regulatory tracker that reads FDA’s warning letters, recalls and policy changes every day, and every prescription is prepared by a state-licensed U.S. pharmacy for one patient. If something FDA publishes touches your care, your provider will tell you.
Sources
- FDA, About Warning and Close-Out Letters (quoted)
- FDA, FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s (March 3, 2026)
- FDA warning letters: 737905 (October 30, 2026); 738238 (September 18, 2026); 728537 (August 7, 2026); 736416 (October 29, 2026)
This information is educational and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved. Treatments require evaluation by a licensed provider.
